Respules Range

Respules — Saturn Formulations PCD Pharma Franchise

Respules — sterile unit-dose nebulisation solutions — represent a critical respiratory drug delivery format for patients who cannot coordinate the hand-breath technique required for metered-dose inhalers (MDIs) or who require higher drug deposition than MDIs can achieve. This includes young children under five years, elderly patients with poor manual dexterity, ICU-ventilated patients, and individuals experiencing severe acute bronchospasm. Saturn Formulations, a WHO-GMP and ISO-certified pharmaceutical manufacturer established in 2012, provides a comprehensive range of Respules covering bronchodilator beta-2 agonists, inhaled corticosteroids, anticholinergic agents, and mucolytics in sterile nebulisation-ready unit-dose ampoule form — enabling PCD Pharma Franchise partners to address the full respiratory nebulisation prescribing spectrum across pulmonology, paediatrics, and emergency medicine settings.

Our respule manufacturing facility operates under aseptic filling conditions in Grade A cleanrooms with validated integrity testing on every unit-dose ampoule. The pharmaceutical quality and sterility assurance of our respule products meets the standards required by pulmonologists who prescribe these products for their most vulnerable patients — infants with bronchiolitis, children with asthma, and adults with COPD in acute exacerbation.

Why Choose Saturn Formulations for Respule Franchise?

• Paediatric Respiratory Essential: Respules are the standard nebulisation format for children under 5 years with asthma and wheeze — a high-volume prescribing population.
• Hospital and Home Care Demand: Respules are used in both inpatient ICU settings and home nebuliser therapy — giving franchise partners both institutional and retail market access.
• Asthma and COPD Epidemic: India has over 30 million asthma patients and 55 million COPD patients — one of the world's largest respiratory disease burdens.
• High Per-Unit Value: Respule unit-dose ampoules command premium pricing compared to oral respiratory medications — improving franchise margins per prescription.
• Sterile Manufacturing Compliance: Our aseptic respule filling facility meets Grade A cleanroom requirements — the quality standard that hospital pharmacy committees mandate.
• Monopoly Territory Rights: Exclusive respule franchise territory for maximum market penetration.

Our Respule Range

Bronchodilator Respules

Salbutamol (Albuterol) 2.5mg/2.5ml unit-dose respule — the most widely used short-acting beta-2 agonist (SABA) for acute asthma and COPD exacerbation management via nebulisation. Salbutamol 5mg/2.5ml high-dose respule for severe acute bronchospasm management. Terbutaline 2.5mg/2ml respule as an alternative SABA bronchodilator. Levosalbutamol 0.63mg and 1.25mg/2.5ml respule — the R-isomer of salbutamol with fewer cardiovascular side effects at equivalent bronchodilator doses.

Ipratropium and Combination Respules

Ipratropium Bromide 250mcg and 500mcg/2ml respule — the anticholinergic nebulisation drug of choice for COPD and as combination therapy in severe acute asthma. Ipratropium 500mcg + Salbutamol 2.5mg combination respule (Combivent-equivalent) for synergistic bronchodilation in COPD acute exacerbations — among the most prescribed hospital nebulisation products in India.

Inhaled Corticosteroid Respules

Budesonide 0.25mg/2ml and 0.5mg/2ml respule — the gold standard inhaled corticosteroid for paediatric asthma management in children under 5 years who cannot use MDI-spacer devices. Budesonide 1mg/2ml for adults requiring higher-dose inhaled steroid via nebulisation. These paediatric asthma products are prescribed by every paediatrician and pulmonologist in India for wheezy infants and toddlers.

Mucolytic Respules

N-Acetylcysteine 300mg/3ml nebulisation solution for mucolytic therapy in chronic suppurative lung disease, COPD, and cystic fibrosis. Hypertonic Saline 3% and 7% nebulisation solution for bronchiolitis, mucociliary clearance enhancement, and cystic fibrosis airway hydration. Dornase Alfa equivalent (rhDNase) preparation for viscous mucus degradation in cystic fibrosis (specialist access). These products represent the specialist tier of nebulisation therapy with high clinical impact.

Antibiotic Nebulisation Solutions

Tobramycin nebulisation solution for Pseudomonas aeruginosa suppression in bronchiectasis and cystic fibrosis. Colistin (Polymyxin E) nebulisation for multidrug-resistant Gram-negative pulmonary infections in ICU patients. Amphotericin B inhalation for invasive pulmonary aspergillosis prophylaxis in immunocompromised patients.

Quality Standards — Respule Manufacturing

Unit-dose respule ampoules are filled under Grade A laminar airflow within Grade B cleanroom environments. Aseptic filling is validated with media fill studies (process simulation) meeting the acceptance criteria of zero contaminated units in 3 consecutive runs of 3000 units each. Every batch undergoes sterility testing per BP/USP, particulate matter testing (light obscuration and microscopic methods), HPLC content assay, pH verification, and container integrity testing by dye ingress or vacuum method. Each respule unit-dose ampoule is individually laser-welded and 100% visually inspected before packaging. Batch sterility assurance level (SAL) is validated at 10^-6 as required for terminally sterilised sterile products.

Start Your Respule Franchise

1. Contact us: +91-8729000609 | enquiry.saturn@gmail.com
2. Select respule SKUs from our respiratory catalogue
3. Submit Drug License (sterile nebulisation products) and GST documents
4. Confirm exclusive territory — hospitals, nursing homes, or retail+clinic
5. Receive products and respiratory specialist promotional materials

Saturn Formulations' Respule franchise gives you specialist respiratory market access across paediatrics, pulmonology, and critical care. Call: +91-8729000609.